PolyPid Stock

PolyPid Equity

The The Equity of PolyPid (PYPD) as of Sep 4, 2026 is 10.97 M USD. In the previous year, The Equity was 7.68 M USD — a change of 42.80% (higher).

Equity

10.97 MUSD

YoY

42.80%

Last updated:

In 2026, PolyPid's equity was 10.97 M USD, a 42.80% increase from the 7.68 M USD equity in the previous year.

The PolyPid Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-81.71 M USD
Jan 1, 2019
30.94 M USD
Jan 1, 2020
72.78 M USD
Jan 1, 2021
35.96 M USD
Jan 1, 2022
5.83 M USD
Jan 1, 2023
-2.10 M USD
Jan 1, 2024
7.68 M USD
Jan 1, 2025
10.97 M USD
The PolyPid Equity history
YEAREquityYoY
10.97 MUSD+42.80%
7.68 MUSD-466.60%
-2.10 MUSD-135.96%
5.83 MUSD-83.79%
35.96 MUSD-50.59%
72.78 MUSD+135.26%
30.94 MUSD-137.86%
-81.71 MUSD-7.82%
-88.65 MUSD+161.04%
-33.96 MUSD+14,600.87%
-231,000.00USD
Access this data via the Eulerpool API

PolyPid Stock analysis

What does PolyPid do? PolyPid Ltd is an innovative, emerging company in the field of biomedical technology based in Israel. The company was founded in 2008 and has since gained continuous recognition and growth. PolyPid's core business is the development and manufacturing of implantable polymer systems that contribute to wound healing. These polymer systems are specifically introduced into the affected area of the body and continuously release active substances to prevent infections and promote natural healing processes. PolyPid's business model is focused on effectively solving patients' problems. The company has developed a wide range of products and technologies that specifically target various medical applications. These include orthopedics, traumatology, urology, and gynecology. For orthopedics, PolyPid provides various products and technologies that can be used in knee and hip joint surgeries. These include antibiotic-releasing implants to prevent infections and resorbable bone fillers that allow for faster and more effective wound healing. In the field of traumatology, PolyPid manufactures polymer systems that are used in the treatment of bone fractures or other traumas. Here again, the polymer systems ensure continuous release of active substances to prevent infections and promote natural healing processes. PolyPid also offers innovative solutions for urology. Specifically, products are developed to combat urinary tract infections and promote faster wound healing after urological surgeries. For gynecology, PolyPid offers polymer systems that can be used particularly in the postoperative phase to prevent infections and achieve faster wound healing. PolyPid has earned an excellent reputation in the industry in recent years due to its consistent focus on innovation and quality. To continually improve their products, the company invests heavily in research and development and maintains close contact with medical institutions and professionals worldwide. PolyPid is an important partner in the field of biomedical technology and has already received numerous awards for its groundbreaking products and developments. Thanks to its focus on quality, reliability, and innovation, the company will continue to play a key role in the biomedical technology market. PolyPid is one of the most popular companies on Eulerpool.

Equity Details

Analyzing PolyPid's Equity

PolyPid's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding PolyPid's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating PolyPid's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

PolyPid's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in PolyPid’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about PolyPid stock

The Equity of PolyPid is 10.97 M USD in 2026.

The Equity of PolyPid changed from 7.68 M USD to 10.97 M USD, representing a 42.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity PolyPid since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's PolyPid historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — PolyPid

All Key Metrics — PolyPid